Natera (NASDAQ:NTRA) Insider Sells $291,683.92 in Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 1,438 shares of Natera stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $202.84, for a total transaction of $291,683.92. Following the transaction, the insider directly owned 185,782 shares of the company’s stock, valued at $37,684,020.88. The trade was a 0.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Fesko also recently made the following trade(s):

• On Friday, May 1st, John Fesko sold 291 shares of Natera stock. The stock was sold at an average price of $206.16, for a total transaction of $59,992.56.
• On Monday, April 27th, John Fesko sold 1,688 shares of Natera stock. The stock was sold at an average price of $204.10, for a total transaction of $344,520.80.
• On Tuesday, March 10th, John Fesko sold 707 shares of Natera stock. The stock was sold at an average price of $204.13, for a total value of $144,319.91.

Natera Trading Up 4.4%

NASDAQ:NTRA opened at $223.37 on Friday. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $256.36. The company has a market cap of $31.99 billion, a price-to-earnings ratio of -137.04 and a beta of 1.57. The stock has a fifty day simple moving average of $202.37 and a 200-day simple moving average of $215.69.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.81. Natera had a negative return on equity of 14.74% and a negative net margin of 9.05%.The business had revenue of $665.50 million during the quarter, compared to the consensus estimate of $600.68 million. During the same period last year, the company earned ($0.41) earnings per share. As a group, equities research analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Key Stories Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced a new collaboration with Diakonos Oncology to use Signatera in a Phase I/II study for refractory melanoma, expanding a key cancer-testing product into another clinical use case and reinforcing its oncology growth story. Article Title
• Positive Sentiment: Canaccord raised its price target on Natera to $250 from $200, signaling stronger confidence in the company’s outlook and helping fuel bullish sentiment. Article Title
• Positive Sentiment: Natera is also drawing attention from investors after commentary calling it a favorite stock idea for the rest of 2026, which adds to the momentum around the name. Article Title

Analysts Set New Price Targets

NTRA has been the subject of several research analyst reports. Evercore reiterated an “outperform” rating and set a $270.00 target price on shares of Natera in a research report on Friday, May 8th. BTIG Research decreased their target price on Natera from $260.00 to $250.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Robert W. Baird set a $265.00 target price on Natera in a research report on Friday, May 8th. William Blair initiated coverage on Natera in a research report on Tuesday, April 14th. They set an “outperform” rating for the company. Finally, Piper Sandler reiterated an “overweight” rating and set a $249.00 target price on shares of Natera in a research report on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Natera has a consensus rating of “Moderate Buy” and an average target price of $256.60.

Institutional Trading of Natera

Several institutional investors and hedge funds have recently made changes to their positions in NTRA. Coatue Management LLC raised its holdings in shares of Natera by 1,446.1% in the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after acquiring an additional 2,463,008 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Natera by 94.7% in the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after acquiring an additional 2,420,263 shares in the last quarter. Norges Bank bought a new stake in shares of Natera in the fourth quarter valued at about $372,398,000. JPMorgan Chase & Co. raised its holdings in shares of Natera by 10.5% in the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after acquiring an additional 1,225,420 shares in the last quarter. Finally, Franklin Resources Inc. raised its holdings in shares of Natera by 37.5% in the third quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock valued at $428,987,000 after acquiring an additional 727,366 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.